Mexichem S.A.B. de C.V. (Tlalnepantla, Mexico; www.mexichem.com) has acquired the distribution and sale license for pharmaceutical grade hfc-227ea/p product for the regulated medical and pharmaceutical propellant market from DuPont fluorochemicals.
For $4.1 million, Mexichem’s Mexichem Limited UK Ltd subsidiary, a division of Mexichem’s Fluor Chain, acquired from E.I. Du Pont de Nemours and Company the distribution and sale license for pharmaceutical grade HFC-227ea/P a medical propellant, supporting the company’s strategy for global growth based on specialty products.
The product is used to safely deliver a variety of drugs and medications in aerosol form, including use in metered-dose inhalers for treatment of asthma. Under the terms of the acquisition, Mexichem has acquired exclusive global rights to sell and distribute the product for the regulated medical and pharmaceutical propellant market, which will be sold under Mexichem’s ZEPHEX brand, the global leader brand of medical propellants with around 75% of inhalers produced worldwide.